UARK 2004-23: A Phase I Study of Multiple Intravenous administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects with B-cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease
Sponsor:
Centocor
PI:
Maurizio Zangari, M.D.
Phase:
I
Purpose:
The purpose of this study is to evaluate five different doses and schedules of CNTO 328 to see which dose/schedule is safe.
Eligibility:
Approximately 10 patients, male and female, age 18 and older, regardless of race or ethnicity, will participate in this study at UAMS.
Treatment:
Depending on when you enter the study, you will be assigned to receive one course of CNTO 328 in one of the following groups:
a) Group 1: 3mg/kg given once every two weeks for 4 infusions
b) Group 2: 6mg/kg given once every two weeks for 4 infusions
c) Group 3: 12mg/kg given once every three weeks for 3 infusions
d) Group 4: 6mg/kg given once a week for seven consecutive weeks
for 7 infusions
e) Group 5: 12mg/kg given once every two weeks for 4 infusions
